• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过[具体物质]和[具体物质]水悬浮液对MRGPRX2受体介导的肥大细胞活化的抑制作用:一项[具体研究类型]研究。 (注:原文中部分内容缺失,需补充完整才能准确翻译)

Inhibition of mast cell activation via MRGPRX2 receptor by and water suspensions: An study.

作者信息

Sahid Muhammad Novrizal Abdi, Mogi Masaki, Maeyama Kazutaka

机构信息

Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Universitas Gadjah Mada, Sekip Utara, Yogyakarta 55281, Indonesia.

Department of Pharmacology, Graduate School of Medicine, Ehime University, Toon-shi, Ehime 791-0295, Japan.

出版信息

Avicenna J Phytomed. 2025 Sep-Oct;15(5):1376-1384. doi: 10.22038/ajp.2024.25199.

DOI:10.22038/ajp.2024.25199
PMID:40969418
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12441196/
Abstract

OBJECTIVE

Traditional medicine is often used to relief pain, but its use is frequently not supported by appropriate scientific information. This study aims to investigate the histamine release suppression of (SA) and (CM).

MATERIALS AND METHODS

Rat peritoneal mast cells (RPMCs) and -transfected RBL-2H3 cells were activated by 50 μg/ml of compound 48/80. Water suspension of SA or CM (0.1-30 mg/ml) was used to inhibit cell activation by compound 48/80. The level of mast cell activation was determined by measuring histamine release concentration using HPLC-fluorometry.

RESULTS

At a concentration of 10 mg/ml, CM resulted in 22.60±5.86% in a spontaneous histamine release from RPMCs. The net histamine release after compound 48/80 stimulation in RPMC was 67.19±1.31%. CM at 3 mg/ml suppressed histamine release to 8.45±2.53%. In -transfected RBL-2H3 cells stimulated with compound 48/80, CM at concentrations of 3 and 10 mg/mL suppressed histamine release to 22.85±0.64% and 4.20±1.60%, respectively. SA at 30 mg/ml induced a spontaneous histamine release of 56.76±4.03%, compared to 5.65±2.61% in the control group. The administration of 3 mg/ml of SA to compound 48/80-stimulated RPMCs resulted in a net histamine release of 6.12±0.46%. In -transfected RBL-2H3 cells activated by compound 48/80, the net release was 35.11±3.10%. SA at 10 mg/ml suppressed histamine release to 4.88±1.42%.

CONCLUSION

SA and CM water suspension suppressed compound 48/80-induced histamine release.

摘要

目的

传统医学常被用于缓解疼痛,但其应用往往缺乏适当的科学依据。本研究旨在探讨[具体物质A](SA)和[具体物质B](CM)对组胺释放的抑制作用。

材料与方法

用50μg/ml的化合物48/80激活大鼠腹膜肥大细胞(RPMCs)和转染[相关基因]的RBL-2H3细胞。SA或CM的水悬浮液(0.1 - 30mg/ml)用于抑制化合物48/80引起的细胞活化。通过高效液相色谱-荧光法测量组胺释放浓度来确定肥大细胞活化水平。

结果

在浓度为10mg/ml时,CM导致RPMCs自发组胺释放率为22.60±5.86%。化合物48/80刺激后RPMCs的组胺净释放率为67.19±1.31%。3mg/ml的CM将组胺释放抑制至8.45±2.53%。在用化合物48/80刺激的转染[相关基因]的RBL-2H3细胞中,3mg/ml和10mg/ml的CM分别将组胺释放抑制至22.85±0.64%和4.20±1.60%。30mg/ml的SA诱导自发组胺释放率为56.76±4.03%,而对照组为5.65±2.61%。向化合物48/80刺激的RPMCs中加入3mg/ml的SA导致组胺净释放率为6.12±0.46%。在由化合物48/80激活的转染[相关基因]的RBL-2H3细胞中,净释放率为35.11±3.10%。10mg/ml的SA将组胺释放抑制至4.88±1.42%。

结论

SA和CM水悬浮液抑制化合物48/80诱导的组胺释放。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9894/12441196/eb5f35a88b4e/AJP-15-1376-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9894/12441196/7988ed887ec3/AJP-15-1376-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9894/12441196/eb5f35a88b4e/AJP-15-1376-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9894/12441196/7988ed887ec3/AJP-15-1376-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9894/12441196/eb5f35a88b4e/AJP-15-1376-g002.jpg

相似文献

1
Inhibition of mast cell activation via MRGPRX2 receptor by and water suspensions: An study.通过[具体物质]和[具体物质]水悬浮液对MRGPRX2受体介导的肥大细胞活化的抑制作用:一项[具体研究类型]研究。 (注:原文中部分内容缺失,需补充完整才能准确翻译)
Avicenna J Phytomed. 2025 Sep-Oct;15(5):1376-1384. doi: 10.22038/ajp.2024.25199.
2
MRGPRX2 Triggers rocuronium bromide-induced peri-operative phase allergic shock: A case report with case control study.MRGPRX2引发罗库溴铵诱导的围手术期过敏性休克:一项病例对照研究的病例报告
Eur J Anaesthesiol. 2025 Sep 18. doi: 10.1097/EJA.0000000000002256.
3
Prescription of Controlled Substances: Benefits and Risks管制药品的处方:益处与风险
4
MRGPRX2 gain-of-function mutation drives enhanced mast cell reactivity in chronic spontaneous urticaria.MRGPRX2功能获得性突变导致慢性自发性荨麻疹中肥大细胞反应性增强。
J Allergy Clin Immunol. 2025 Jul;156(1):159-170. doi: 10.1016/j.jaci.2025.03.007. Epub 2025 Mar 18.
5
A TCM formula VYAC ameliorates DNCB-induced atopic dermatitis via blocking mast cell degranulation and suppressing NF-κB pathway.中药配方 VYAC 通过阻断肥大细胞脱颗粒和抑制 NF-κB 通路改善 DNCB 诱导的特应性皮炎。
J Ethnopharmacol. 2021 Nov 15;280:114454. doi: 10.1016/j.jep.2021.114454. Epub 2021 Jul 28.
6
Tachykinin-1 receptor antagonism suppresses substance-P- and compound 48/80-induced mast cell activation from rat mast cells expressing functional mas-related GPCR B3.速激肽-1 受体拮抗作用抑制表达功能性 mas 相关 GPCR B3 的大鼠肥大细胞中 P 物质和化合物 48/80 诱导的肥大细胞活化。
Inflamm Res. 2020 Mar;69(3):289-298. doi: 10.1007/s00011-020-01319-z. Epub 2020 Jan 28.
7
Oral morphine for cancer pain.口服吗啡用于癌症疼痛。
Cochrane Database Syst Rev. 2016 Apr 22;4(4):CD003868. doi: 10.1002/14651858.CD003868.pub4.
8
[Preparation of calcium phosphate nanoflowers and evaluation of their antioxidant and osteogenic induction capabilities ].磷酸钙纳米花的制备及其抗氧化和成骨诱导能力的评估
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2025 Sep 15;39(9):1203-1211. doi: 10.7507/1002-1892.202506018.
9
A randomized crossover design study comparing the pharmacokinetics and pharmacodynamics of 2 single doses of oral aspirin (75 mg v 150 mg) in pregnant women at risk of preeclampsia: implications on assessing aspirin response and patient adherence to therapy.一项随机交叉设计研究,比较两剂单剂量口服阿司匹林(75毫克对150毫克)在有先兆子痫风险的孕妇中的药代动力学和药效学:对评估阿司匹林反应及患者治疗依从性的意义
Am J Obstet Gynecol. 2025 May;232(5):474.e1-474.e15. doi: 10.1016/j.ajog.2024.10.023. Epub 2024 Oct 21.
10
Linzagolix with and without hormonal add-back therapy for symptomatic uterine fibroids: PRIMROSE 1 & 2 long-term extension and withdrawal study.使用和不使用激素补充疗法的林扎戈利克治疗有症状子宫肌瘤:PRIMROSE 1和2长期扩展与撤药研究。
Fertil Steril. 2025 Jun 19. doi: 10.1016/j.fertnstert.2025.06.016.